Browse Studies — Arctuva

Phase 3

GAIN-BCG: Gemcitabine Alternating With INtravesical BCG Randomized Against BCG Alone for Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer

This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with no…

Recurrent Non-Muscle Invasive Bladder CarcinomaStage 0a Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8

Estimated

~$10 – $6,250

Alliance for Clinical Trials in OncologyNCT07000084

Phase 2

A Scalable Cruciferous Vegetable Intervention to Reduce Bladder Cancer Recurrence and Progression

This phase II trial is being done to develop and test a healthy eating program to reduce cancer recurrence (cancer that has come back after a period of improve…

Non-Muscle Invasive Bladder CarcinomaRecurrent Bladder CarcinomaRecurrent Non-Muscle Invasive Bladder Carcinoma+2 more

Estimated

~$10 – $7,500

Roswell Park Cancer InstituteNCT06733363

Phase 1

A Phase I Microtrial With PLZ4-Coated Paclitaxel-Loaded Micelles (PPM) in Patients With Recurrent or Refractory Non-Myoinvasive Bladder Cancer

This phase I trial tests the safety, tolerability and effectiveness of PLZ4-coated paclitacel-loaded micelles (PPM) in treating patients with non-muscle invasi…

Recurrent Non-Muscle Invasive Bladder CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8+1 more

Estimated

~$10 – $6,250

University of California, DavisNCT06173349